Attached files
| file | filename |
|---|---|
| S-1/A - S-1/A - ALPINE IMMUNE SCIENCES, INC. | a2224904zs-1a.htm |
| EX-5.1 - EX-5.1 - ALPINE IMMUNE SCIENCES, INC. | a2224904zex-5_1.htm |
| EX-1.1 - EX-1.1 - ALPINE IMMUNE SCIENCES, INC. | a2224904zex-1_1.htm |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 17, 2015 (except Notes 3, 6, 8, 11 and 12, as to which the date is June 3, 2015) in Amendment No. 1 to the Registration Statement (Form S-1 No. 333-204127) and the related Prospectus of Nivalis Therapeutics, Inc. for the registration of 4,285,714 shares of its common stock.
|
|
/s/ Ernst & Young LLP |
Denver, Colorado
June 3, 2015